Hematology

Latest News
May 29th 2025

CLL Linked With Worse COVID-19 Outcomes in Early Pandemic

May 28th 2025

CD20 Levels May Impact BsAb Response in B-Cell Lymphomas

May 23rd 2025

Early Relapse After CAR T-Cell Therapy Linked With Poor BsAb Outcomes in LBCL

May 22nd 2025

Safety, Efficacy of Luspatercept for MDS Confirmed in Real-World Setting

May 17th 2025

Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo
Video Interviews
View All
May 20th 2025

MRD Status Guides Consolidation With Cema-Cel in ALPHA3 Trial: Fred Locke, MD

May 15th 2025

Benefits of Continuing Subcutaneous Daratumumab After Initial Quad Therapy: Pieter Sonneveld, MD, PhD

May 15th 2025

Switching Patients With CLL From Ibrutinib for Zanubrutinib: Mohit Narang, MD

May 14th 2025

Future Research Priorities for Non-Hodgkin Lymphomas: Craig A. Portell, MD

May 5th 2025

"Exceptionally Long" PFS Projected With Daratumumab Quadruplet for Multiple Myeloma: Pieter Sonneveld, MD, PhD

May 1st 2025

Considerations for Real-World MM Treatment: Ajai Chari, MD

April 27th 2025

Fatigue, Quality of Life Improve With Rusfertide: Andrew Kuykendall, MD

April 21st 2025

Cema-Cel Data Highlight Potential in Allogeneic CAR T: Fred Locke, MD

April 18th 2025

Navigating Value, Efficacy in Modern CLL Treatment: Pierluigi Porcu, MD

April 10th 2025

Rusfertide Cuts Phlebotomy Need in Polycythemia Vera: Andrew Kuykendall, MD

Podcasts
View All
July 16th 2024

Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH

September 15th 2018

Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News

May 5th 2018

Podcast: This Week in Managed Care—Insurance Coverage Gains Reverse and Other Health News

March 10th 2018

Podcast: This Week in Managed Care—Verma on Health Data and Other Health News

December 16th 2017

Podcast: This Week in Managed Care—CAR T Treatments and Other Health News

December 14th 2017

Five Years of Reducing Overuse of Medical Services With Choosing Wisely

More News

Overall, there were 36 factors identified as having a prognostic impact on at least 1 clinical outcome. | Image Credit: laszlo - stock.adobe.com
May 16th 2025

Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

AJMC Contributor
A systematic review and subsequent expert review gave comprehensive insight into prognostic factors for patients receiving treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Patients with relapsed/refractory disease achieved an ORR of 63% in the phase 2 study. | Image Credit: Eleni - stock.adobe.com
May 16th 2025

Bexmarilimab Plus Azacitidine Meets ORR End Point in R/R Higher-Risk MDS

Courtney Flaherty
The addition of bexmarilimab to azacitidine elicited an ORR of 63% among patients with relapsed/refractory higher-risk myelodysplastic syndrome.
Other AF prediction models have been proposed, including one with a machine-learning approach, but earlier models may not apply to patients taking second-generation BTKis. | Image Credit: sovova - stock.adobe.com
May 15th 2025

Novel AI-Based Score Could Pinpoint AF Risk in Patients With CLL on BTKis

Jared Kaltwasser
A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) develop atrial fibrillation (AF).
One of the key ways to manage thromboembolic event risk in PV is by controlling hematocrit, often by prescribing hydroxyurea. If patients develop resistance to the therapy, however, they face a higher risk of mortality. | Image credit: keetazalay - stock.adobe.com
May 6th 2025

Machine Learning Model Identifies Hydroxyurea Resistance Markers in PV

Jared Kaltwasser
Machine learning identifies key biomarkers predicting hydroxyurea resistance in polycythemia vera, enhancing early treatment strategies and patient outcomes.
While both are anti-CD20 antibodies, obinutuzumab is a glycoengineered type II CD20 antibody, and rituximab is a type I CD20 antibody, meaning a different mode of binding to CD20 antigen. | Image credit: Eleni - stock.adobe.com
May 1st 2025

Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL

AJMC Contributor
Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall survival with obinutuzumab and chlorambucil (G-Clb) compared with chemotherapy plus rituximab or chemotherapy alone for chronic lymphocytic leukemia (CLL).
Researchers analyzed matched cohorts of patients who received either decitabine-cedazuridine with venetoclax or decitabine-cedazuridine alone to determine how the addition of venetoclax impacts outcomes in higher-risk MDS and CMML. |Image credit: syahrir - stock.adobe.com
April 25th 2025

Adding Venetoclax to Decitabine-Cedazuridine Improves Response in MDS Subgroups

Rose McNulty
Adding venetoclax to decitabine-cedazuridine significantly enhanced response rates in patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia.
Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com
April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Kyle Munz Ajai Chari, MD
When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
The investigators found that people with MPNs and at least one CVRF had an increased risk of both death and arterial or venous thrombosis. | Image credit: Dr_Microbe - stock.adobe.com
April 21st 2025

Cardiovascular Risk Factors Impact Outcomes in MPNs

Jared Kaltwasser
Cardiovascular risk factors increase the risk of arterial and venous thrombosis in patients with myeloproliferative neoplasms, a study found.
Acalabrutinib is a second-generation BTKi with reduced cardiovascular toxicity and an overall better safety profile compared with ibrutinib. | Image credit: Laszlo - stock.adobe.com
April 20th 2025

Acalabrutinib Combos Improve PFS vs CIT in First-Line CLL

AJMC Contributor
Acalabrutnib plus venetoclax, with or without obinutuzumab, improved progression-free survival (PFS) compared with chemoimmunotherapy (CIT) in patients with untreated chronic lymphocytic leukemia (CLL), meeting the phase 3 AMPLIFY study’s primary endpoint.
While pausing therapy did not affect response to vaccination, the investigators noted that participants who paused therapy did have higher rates of self-reported lymphadenopathy. | Image credit: Konstantin Yuganov - stock.adobe.com
April 18th 2025

Pausing BTK Inhibitors Does Not Strengthen COVID Vaccination in CLL

Jared Kaltwasser
Previous work had suggested pausing Bruton tyrosine kinase (BTK) inhibitors before COVID-19 vaccination might boost immunity in patients with chronic lymphocytic leukemia (CLL).
Multigenerational | Image Credit: © DisobeyArt-stock.adobe.com
April 16th 2025

DLBCL Outcomes Vary Sharply for Patients 80 Years and Older

Maggie L. Shaw
A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are diagnosed in patients 65 years and older; these patients are a heterogeneous group, and few studies have investigated how their outcomes are influenced by patient characteristics and care management regimens.
In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com
April 15th 2025

Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

Jared Kaltwasser
Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.
Orca-T shows promise to reduce rehospitalization and improve outcomes in MDS and acute leukemias.| Image credit: Eleni - stock.adobe.com
April 11th 2025

Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS: Caspian Oliai, MD, MS

Mary Caffrey Caspian Oliai, MD, MS Rose McNulty
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
The researchers examined outcomes in a series of patients with RT who were treated with liso-cel, including patients who were also taking ibrutinib. | Image credit: AIGen - stock.adobe.com
April 10th 2025

Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation

Jared Kaltwasser
Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.
Recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia. | Image credit: Spectral-Design - stock.adobe.com
April 8th 2025

Immune Microenvironment a Key Target in CLL

Jared Kaltwasser
A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).
Health equity concept | image credit: VectorMine - stock.adobe.com
April 7th 2025

Advancing MM Care Through Innovation and Equity: Ajai Chari, MD

Kyle Munz Ajai Chari, MD
Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial for maximizing their impact in multiple myeloma (MM).
CAR T in NHL | Image Credit: © LASZLO-stock.adobe.com
April 3rd 2025

Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL

Maggie L. Shaw
In this comparative analysis, patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) received bridging therapy via radiation or systemic treatment while their chimeric antigen receptor T-cell therapy (CAR T) was being manufactured.
Targeting GPRC5D Holds Promise in Multiple Myeloma
April 3rd 2025

Targeting GPRC5D Holds Promise in Multiple Myeloma

Jared Kaltwasser
Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment strategies.
Patient and doctor discussing symptoms. | Image credit: Intelligent Horizons - stock.adobe.com.jpeg
April 3rd 2025

PROs Associated With Survival, AEs in Multiple Myeloma

Jared Kaltwasser
The study highlights the importance of including patient self-assessment—and not just clinician assessment—when planning treatment in multiple myeloma.
Andrew Kuykendall, MD, Moffitt Cancer Center
April 1st 2025

Reducing Polycythemia Vera–Associated Thrombotic Risk Through Iron Regulation

Maggie L. Shaw Andrew Kuykendall, MD
In part 3 of a discussion with Andrew Kuykendall, MD, Moffitt Cancer Center, he talks of rusfertide’s ability to enable patients to live a more viable life and free them from being tethered to the need for regular phlebotomies.
FDA approval-Olivier Le Moal-stock.adobe.com
March 28th 2025

FDA Approves Fitusiran for Reducing Bleeds in Patients With Hemophilia A/B

Giuliana Grossi
Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on the safety and efficacy of fitusiran (Qfitlia; Sanofi).
ESA treatment before or early after regular transfusion therapy improved OS In lower-risk MDS, a new study found. | Image credit: MdBabul - stock.adobe.com
March 28th 2025

ESA Treatment Improves OS in Lower-Risk MDS

Rose McNulty
Erythropoiesis-stimulating agent (ESA) treatment before or early after regular transfusion therapy improved overall survival (OS) In lower-risk myelodysplastic syndromes (MDS), a new study found.
Ajai Chari, MD
March 27th 2025

Optimizing Patient Selection for CAR T, Bispecifics Mitigates Adverse Events in High-Risk MM

Kyle Munz Ajai Chari, MD
For higher-risk multiple myeloma (MM), successful patient selection and monitoring strategies are vital for the management of adverse events and the disease itself.
ASH logo | images: ASH
March 24th 2025

Amid NIH Cuts, ASH Expands Eligibility for Midcareer Research Awards

Mary Caffrey
The American Society of Hematology (ASH) was already looking to expand its Bridge Grant program when changes to the National Institutes of Health (NIH) funding landscape created greater urgency.
CAR T | Image Credit: © Funny-stock.adobe.com
March 21st 2025

Overcoming CAR T Manufacturing Failure in LBCL

Maggie L. Shaw
Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen receptor (CAR) T-cell administration in patients with relapsed/refractory large B-cell lymphoma (LBCL).
Woman taking pills from bottle | Image credit: Rawpixel.com – stock.adobe.com
March 20th 2025

In CLL, Zanubrutinib Shows Better Safety Profile Than Ibrutinib

Hayden E. Klein
A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events among those treated with zanubrutinib compared with ibrutinib.
Orca-T is manufactured with highly purified regulatory T cells, hematopoietic stem cells, and conventional T cells from peripheral blood from matched donors. | Image credit: fotogurmespb - stock.adobe.com.jpg
March 20th 2025

Orca-T Immunotherapy Improves cGVHD-Free Survival in ALL, AML, MDS

Rose McNulty
The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who received standard allogeneic stem cell transplant for hematologic malignancies.
Andrew Kuykendall, MD, Moffitt Cancer Center
March 19th 2025

Understanding Hematocrit Thresholds in Polycythemia Vera Treatment

Maggie L. Shaw Andrew Kuykendall, MD
Treatment guidelines in polycythemia vera currently recommend maintaining hematocrit below 45%, with a higher threshold for men vs women.
CLL | Image credit: jarun011 – stock.adobe.com
March 19th 2025

Newer CLL Therapies Show Superior Long-Term Disease Control

Hayden E. Klein
Researchers also highlighted the significance of TTNT-D as a real-world measure of treatment efficacy, noting it provides insight into both clinical and patient-centered outcomes.
Frederick L. Locke, MD, Moffitt Cancer Center and Research Institute
March 17th 2025

Gene Editing for Safer CAR T-Cell Therapy in Large B-Cell Lymphoma

Maggie L. Shaw Frederick L. Locke, MD
Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma.
12345678
...
26>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo